In Vivo CRO Market Growth, Size, Trends, Revenue, Challenges and Future Outlook
In Vivo CRO Market Growth, Size, Trends Analysis - By Model Type, By Modality, By Indication - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: May-2025 | Report ID: HLCA25131 | Pages: 1 - 250 | Formats*: |
| Category : Healthcare | |||
In Vivo CRO Market Introduction and Overview
According to SPER Market Research, the Global In Vivo CRO Market is estimated to reach USD 11.47 billion by 2034 with a CAGR of 8.38%.
The report includes an in-depth analysis of the Global In Vivo CRO Market, including market size and trends, product mix, Applications, and supplier analysis. The in vivo CRO market is projected to expand at an 8.38% annual rate between 2025 and 2034, from its 2024 valuation of USD 5.13 billion. Key factors driving this growth include the rising number of cancer patients, increased in vivo pharmacology studies, and more pharma and biotechnology companies focusing on new treatments. The increase in CROs, research activities, and studies will also contribute to market growth, along with investments in gene-modified cell therapies.
By Model Type Insights:
The market is divided into rodent-based and non-rodent-based segments based on model type. The category based on rodents is further divided into models of rats, mice, and other animals. Due to their usage as models in medical research because of their behavioural, biological, and genetic parallels to humans, rats accounted for the greatest portion of the market in 2024. They are the most common species in medical research because of their widespread use in medical trials and studies.
By Modality Insights:
The market is divided into two segments: small molecules and large molecules, according to modality. The in vivo CRO market's highest share in 2024 was held by the small molecules category. Highly Potent Active Pharmaceutical Ingredients (HPAPI), small molecule APIs, and other tiny compounds are all being researched. Compared to large compounds, there are a lot more small molecule medication prospects. Additionally, with a great deal of scholarly study for new targets, these compounds aid in the preclinical and clinical development of medication candidates. Similarly, the market is expected to be driven by an increase in FDA approvals for small molecules.
By Indication Insights:
The market is divided into segments based on specific conditions such as autoimmune/inflammation, pain management, oncology, CNS conditions, diabetes, obesity, and others. The oncology segment led the global in vivo CRO market and represented a significant revenue share in 2024. Mouse models are preferred for human cancer research in in vivo studies due to their similar traits to humans. Mice share many key genetic and anatomical features with humans, particularly RNI-like genes, which are over 80% similar to human genes. The most common models for tumor research are immunodeficient and immunocompetent mice with xenografted or syngeneic tumors. These aspects contribute to the segment's leading share.
Regional Insights:
North America's market held the largest share in 2024 due to advanced Contract Research Organizations (CROs) and increased government grants, such as those from the National Institute of Health (NIH), that promote research. The region's reputable CROs and extensive drug development activities, along with numerous pharmaceutical and biotech companies, are driving market growth. In contrast, the Asia Pacific in vivo CRO market is projected to grow at the fastest rate during the forecast period. This growth is due to the affordability of CROs in India and China, economic development, and advanced healthcare infrastructure. Additionally, rising partnerships and outsourcing of in vivo services to emerging economies will contribute to this growth.
Market Competitive Landscape:
The in vivo CRO sector is distinguished by the existence of several important players that provide innovative services. Strategic alliances, mergers, and acquisitions are frequent methods used by players to increase market presence, improve service portfolios, and achieve a competitive edge. Key market players are IQVIA Inc, Crown Bioscience, Taconic Biosciences, Inc, PsychoGenics Inc, Evotec, Janvier Labs, among others.
Recent Developments:
Lindus Health launched an all-in-one medical device CRO service in June 2024, combining in-vivo CRO expertise with advanced technology and recruitment strategies to streamline clinical trials and accelerate participant enrolment across multiple therapeutic areas and regulatory pathways.
The acquisition of SYNCROSOME was announced by ETAP-Lab on October 20, 2023. SYNCROSOME is a contract research organisation that provides preclinical in vivo pharmacology services with a focus on cardiovascular disease. The acquisition is a step towards achieving ETAP-Lab's strategy and expanding the company's position as a leading preclinical CRO.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Model Type, By Modality, By Indication |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | IQVIA Inc, Crown Bioscience, Taconic Biosciences, Inc, PsychoGenics Inc, Evotec, Janvier Labs, Biocytogen Boston Corp, GemPharmatech, Charles River Laboratories, Icon Plc. |
- Global In Vivo CRO Market Size (FY’2021-FY’2034)
- Overview of Global In Vivo CRO Market
- Segmentation of Global In Vivo CRO Market By Model Type (Rodent Based, Non-Rodent Based)
- Segmentation of Global In Vivo CRO Market By Modality (Small Molecule, Large Molecule)
- Segmentation of Global In Vivo CRO Market By Indication (Oncology, CNS Conditions, Diabetes, Obesity, Pain management, Autoimmune/inflammation conditions, Others)
- Statistical Snap of Global In Vivo CRO Market
- Expansion Analysis of Global In Vivo CRO Market
- Problems and Obstacles in Global In Vivo CRO Market
- Competitive Landscape in the Global In Vivo CRO Market
- Details on Current Investment in Global In Vivo CRO Market
- Competitive Analysis of Global In Vivo CRO Market
- Prominent Players in the Global In Vivo CRO Market
- SWOT Analysis of Global In Vivo CRO Market
- Global In Vivo CRO Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER’s internal database
- 2.1.4. Premium insight from KOL’s
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTER’s Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global In Vivo CRO Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global In Vivo CRO Market
7. Global In Vivo CRO Market, By Model Type (USD Million) 2021-2034
- 7.1. Rodent based
- 7.1.1. Rat Models
- 7.1.2. Mice Models
- 7.1.3. Others
- 7.2. Non-Rodent based
8. Global In Vivo CRO Market, By Modality (USD Million) 2021-2034
- 8.1. Small Molecules
- 8.2. Large Molecules
- 8.2.1. Cell & Gene Therapy
- 8.2.1. CAR T-cell therapies
- 8.2.1. CAR-NK cell therapy
- 8.2.1. TCR-T cell therapy
- 8.2.1. Other
- 8.2.2. RNA Therapy
- 8.2.3. Others
9. Global In Vivo CRO Market, By Indication (USD Million) 2021-2034
- 9.1. Oncology
- 9.1.1. Blood cancer
- 9.1.2. Solid tumor
- 9.1.3. Others
- 9.2. CNS Conditions
- 9.2.1. Epilepsy
- 9.2.2. Parkinson's disease
- 9.2.3. Huntington's disease
- 9.2.4. Stroke
- 9.2.5. Muscular Dystrophy
- 9.2.6. Alzheimer’s Disease
- 9.2.7. Traumatic brain injury
- 9.2.8. Amyotrophic lateral sclerosis (ALS)
- 9.2.9. Spinal Muscular Atrophy
- 9.2.10. Muscle regeneration
- 9.2.11. Other Neurodevelopment Disorders
- 9.3. Diabetes
- 9.4. Obesity
- 9.5. Pain management
- 9.5.1. Chronic pain
- 9.5.2. Acute pain
- 9.6. Autoimmune/inflammation conditions
- 9.6.1. Rheumatoid Arthritis
- 9.6.2. Multiple Sclerosis
- 9.6.3. Osteoarthritis
- 9.6.4. Irritable Bowel Syndrome
- 9.6.5. Others
- 9.7. Others
10. Global In Vivo CRO Market, (USD Million) 2021-2034
- 10.1. Global In Vivo CRO Market Size and Market Share
11. Global In Vivo CRO Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. IQVIA Inc
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Crown Bioscience
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Taconic Biosciences, Inc
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. PsychoGenics Inc
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. Evotec
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Janvier Labs
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Biocytogen
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. GemPharmatech
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Charles River Laboratories
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Icon Plc
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
In Vivo CRO Market is projected to reach USD 11.47 billion by 2034, growing at a CAGR of of 8.38% during the forecast period.
In Vivo CRO Market grew in Market size from 2025. The Market is expected to reach USD 11.47 billion by 2034, at a CAGR of 8.38% during the forecast period.
In Vivo CRO Market CAGR of 8.38% during the forecast period.
You can get the sample pages by clicking the link - Click Here
In Vivo CRO Market size is USD 11.47 billion from 2025 to 2034.
In Vivo CRO Market is covered By Model Type, By Modality, By Indication
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the In Vivo CRO Market.
IQVIA Inc, Crown Bioscience, Taconic Biosciences, Inc, PsychoGenics Inc, Evotec, Janvier Labs, Biocytogen Boston Corp, GemPharmatech, Charles River Laboratories, Icon Plc.
The report includes an in-depth analysis of the Global In Vivo CRO Market, including market size and trends, product mix, Applications, and supplier analysis
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
